Cited by 3,481Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Open access

Gibb, W R, Lees, A J·1988·Journal of Neurology, Neurosurgery & Psychiatry

DOI 10.1136/jnnp.51.6.745PMC PMC1033142

Open this paper in CoChat — free account Open PDF

Abstract

The Lewy body is a distinctive neuronal inclusion that is always found in the substantia nigra and other specific brain regions in Parkinson's disease. It is mainly composed of structurally altered neurofilament, and occurs wherever there is excessive loss of neurons. It occurs in some elderly individuals and rarely in other degenerative diseases of the central nervous system. In 273 brains of patients dying from disorders other than Parkinson's disease, the age-specific prevalence of Lewy bodies increased from 3.8% to 12.8% between the sixth and ninth decades. Associated pathological findings suggest that these cases of incidental Lewy body disease are presymptomatic cases of Parkinson's disease, and confirm the importance of age (time) in the evolution of the disease. In view of the common and widespread occurrence of this disorder we propose that endogenous mechanisms operating in early life may be more important than environmental agents in the pathogenesis of Lewy bodies and Parkinson's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/jnnp.51.6.745

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
Basal forebrain neurons in the dementia of Parkinson disease
Whitehouse, P. J., Hedreen, J. C., White, C. L., & Price, D. L. (1983) · Annals of Neurology · doi:10.1002/ana.410130304 · Cited by 535
AETIOLOGY OF PARKINSON'S DISEASE
Calne, D., & Langston, J. W. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90802-4 · Cited by 469
Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?
Kosaka, K., Yoshimura, M., Ikeda, K., & Budka, H. (1984) · PubMed · Cited by 401
Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys
Forno, L. S., Langston, J. W., DeLanney, L. E., Irwin, I., & Ricaurte, G. A. (1986) · Annals of Neurology · doi:10.1002/ana.410200403 · Cited by 351
Parkinson's disease in 65 pairs of twins and in a set of quadruplets
Ward, C. D., Duvoisin, R. C., Ince, S. E., Nutt, J., Eldridge, R., & Calne, D. B. (1983) · Neurology · doi:10.1212/wnl.33.7.815 · Cited by 347
PHASE AND ELECTRON MICROSCOPIC OBSERVATIONS OF LEWY BODIES AND MELANIN GRANULES IN THE SUBSTANTIA NIGRA AND LOCUS CAERULEUS IN PARKINSONʼS DISEASE
Duffy, P. E., & Tennyson, V. M. (1965) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-196507000-00003 · Cited by 345
THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE
Gibb, W. R. G., & Lees, A. J. (1989) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1989.tb01147.x · Cited by 325
Self-citation
Esophageal Lewy bodies associated with ganglion cell loss in achalasia
Qualman, S. J., Haupt, H. M., Yang, P. H., & Hamilton, S. R. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90079-9 · Cited by 305
Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease.
Qualman, S. J., Haupt, H. M., Yang, P. H., & Hamilton, S. R. (1984) · PubMed · Cited by 295

Show all 39 references

Research works printed but not linked: 7

Gibb WRG. The Lewy body and Parkinson's disease. In: Clifford Rose F, ed. Parkinson's Disease: Clinical and Experimental Advances. London: John Libbey and Co, 1987:3-11.
Oppenheimer D. Neuropathology of progressive autonomic failure. In: Bannister R, ed. Autonomic failure. Oxford University Press, London, 1983:267-83.
Sigwald J, Lapresle J, Raverdy P, Recondo NJ. Atrophie cerebelleuse familiale avec association de lesions nigeriennes et spinales. Presse Med 1964;72:557-62.
Vogt C, Vogt 0. Erkrankungen der GroBhirnrinde im Lichte der Topistik, Pathoklise und Pathoarchitektonik. J Psychol Neurol 1922;28:1-171.
Hamada S, Ishii T. The Lewy body in the brain of the aged. Adv Neurol Sci 1963;7:184-6.
Hirai S. Ageing of the substantia nigra. Adv Neurol Sci 1968;12:845-9.
Hassler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 1938;48:387-476.

Sorted by citations

Items 301–400 of 1,022

Study of Circadian Melatonin Secretion Pattern at Different Stages of Parkinson's Disease
Bordet, R., Devos, D., Brique, S., Touitou, Y., Guieu, J. D., Libersa, C., & Destée, A. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200303000-00005 · Cited by 184
Do α-synuclein aggregates in autonomic plexuses predate Lewy body disorders?
Mínguez‐Castellanos, A., Chamorro, C. E., Sevilla, F. E., Ortega-Moreno, A., Rebollo, A. C., Gómez-Río, M., Concha, A., & Muñoz, D. G. (2007) · Neurology · doi:10.1212/01.wnl.0000264429.59379.d9 · Cited by 183
Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder
Stefani, A., Iranzo, Á., Holzknecht, E., Perra, D., Bongianni, M., Gaig, C., Heim, B., Serradell, M., Sacchetto, L., Garrido, A., et al. (2021) · Brain · doi:10.1093/brain/awab005 · Cited by 178
CSF Aβ42 and tau in Parkinson's disease with cognitive impairment
Montine, T. J., Shi, M. Y., Quinn, J. F., Peskind, E. R., Craft, S., Ginghină, C., Chung, K. A., Kim, H., Galasko, D. R., Jankovic, J. J., et al. (2010) · Movement Disorders · doi:10.1002/mds.23287 · Cited by 185
Activities of daily living and quality of life in persons with newly diagnosed Parkinson’s disease according to subtype of disease, and in comparison to healthy controls
Hariz, G.-M., & Forsgren, L. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01344.x · Cited by 192
Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging
Choi, H., Ha, S., Im, H. J., Paek, S. H., & Lee, D. S. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.09.010 · Cited by 186
18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study
Schonhaut, D. R., McMillan, C. T., Spina, S., Dickerson, B. C., Siderowf, A., Devous, M. D., Tsai, R., Winer, J., Russell, D. S., Litvan, I., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25060 · Cited by 175
Catechol O -Methyltransferase val 158 met Genotype Influences Frontoparietal Activity during Planning in Patients with Parkinson's Disease
Williams‐Gray, C. H., Hampshire, A., Robbins, T. W., Owen, A. M., & Barker, R. A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0774-07.2007 · Cited by 181
Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers
Mesa-Herrera, F., Taoro‐González, L., Valdés‐Baizabal, C., Díaz, M. L., & Marín, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153810 · Cited by 191
Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
Booij, J., Habraken, J. B. A., Bergmans, P., Tissingh, G., Winogrodzka, A., Wolters, E. C., Janssen, A. G. M., Stoof, J. C., & van Royen, E. A. (1998) · PubMed · Cited by 178
Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies
Tam, C. W. C., Burton, E. J., McKeith, I. G., Burn, D. J., & O’Brien, J. T. (2005) · Neurology · doi:10.1212/01.wnl.0000153070.82309.d4 · Cited by 209
Essential tremor course and disability
Rajput, A., Robinson, C., & Rajput, A. (2004) · Neurology · doi:10.1212/01.wnl.0000115145.18830.1a · Cited by 96
Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease
Narayanan, N. S., Rodnitzky, R. L., & Uc, E. Y. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0004 · Cited by 181
Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study
Nègre‐Pagès, L., Grandjean, H., Lapeyre‐Mestre, M., Montastruc, J. L., Fourrier, A., Lepine, J. P., Rascol, O., & on behalf of the DoPaMiP Study Group (2009) · Movement Disorders · doi:10.1002/mds.22760 · Cited by 176
SNCA Variant Associated With Parkinson Disease and Plasma α-Synuclein Level
Mata, I. F., Shi, M. Y., Agarwal, P., Chung, K. A., Edwards, K. L., Factor, S. A., Galasko, D. R., Ginghină, C., Griffith, A., Higgins, D. S., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.279 · Cited by 177
Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific
Taki, J., Nakajima, K., Hwang, E.-H., Matsunari, I., Komai, K., Yoshita, M., Sakajiri, K., & Tonami, N. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050544 · Cited by 176
Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD
Pyle, A., Foltynie, T., Tiangyou, W., Lambert, C., Keers, S. M., Allcock, L. M., Davison, J., Lewis, S. J. G., Perry, R. H., Barker, R. A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20417 · Cited by 176
Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study)
Olanow, C. W., Damier, P., Goetz, C. G., Mueller, T. J., Nutt, J. G., Rascol, O., Serbanescu, A., Deckers, F., & Russ, H. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200403000-00003 · Cited by 175
Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?
Frigerio, R., Fujishiro, H., Ahn, T. B., Josephs, K. A., Maraganore, D. M., DelleDonne, A., Parisi, J. E., Klos, K. J., Boeve, B. F., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.019 · Cited by 172
The prediagnostic phase of Parkinson's disease
Noyce, A. J., Lees, A. J., & Schrag, A. E. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311890 · Cited by 187
Self-citation
Phytochemical and Pharmacological Role of Liquiritigenin and Isoliquiritigenin From Radix Glycyrrhizae in Human Health and Disease Models
Ramalingam, M., Kim, H., Lee, Y., & Lee, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00348 · Cited by 180
The evolution of primary progressive apraxia of speech
Josephs, K. A., Duffy, J. R., Strand, E. A., Machulda, M. M., Senjem, M. L., Gunter, J. L., Schwarz, C. G., Reid, R. I., Spychalla, A. J., Lowe, V. J., et al. (2014) · Brain · doi:10.1093/brain/awu223 · Cited by 177
Role of mitochondria in the etiology and pathogenesis of Parkinson's disease
Mizuno, Y., Ikebe, S., Hattori, N., Nakagawa-Hattori, Y., Mochizuki, H., Tanaka, M., & Ozawa, T. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00038-6 · Cited by 170
The nonmotor symptoms of Parkinson's disease—An overview
Lim, S., & Lang, A. E. (2010) · Movement Disorders · doi:10.1002/mds.22786 · Cited by 171
The 39 item Parkinson's disease questionnaire (PDQ-39) revisited: implications for evidence based medicine
Hagell, P., & Nygren, C. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.111161 · Cited by 179
The role of genetics in Parkinson’s disease: a large cohort study in Chinese mainland population
Zhao, Y., Qin, L., Pan, H., Liu, Z., Li, J., He, Y., Zeng, Q., Zhou, X. C., Zhou, X., Zhou, Y., et al. (2020) · Brain · doi:10.1093/brain/awaa167 · Cited by 162
The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease
Broussolle, E., Dentresangle, C., Landais, P., Garcı́a-Larrea, L., Pollak, P., Croisile, B., Hibert, O., Bonnefoi, F., Galy, G., Froment, J. C., et al. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00127-6 · Cited by 169
Is R2* a New MRI Biomarker for the Progression of Parkinson’s Disease? A Longitudinal Follow-Up
Ulla, M., Bonny, J.-M., Ouchchane, L., Rieu, I., Claise, B., & Durif, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057904 · Cited by 167
Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease
Martínez‐Martín, P., Valldeoriola, F., TOLOSA, E. S., Pilleri, M., Molinuevo, J. L., Rumià, J., & Ferrer, E. (2002) · Movement Disorders · doi:10.1002/mds.10044 · Cited by 167
Long Non-Coding RNA and Alternative Splicing Modulations in Parkinson's Leukocytes Identified by RNA Sequencing
Soreq, L., Guffanti, A., Salomonis, N., Simchovitz, A., Israel, Z. H., Bergman, H., & Soreq, H. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003517 · Cited by 170
Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein
Bernis, M. E., Babila, J. T., Breid, S., Wüsten, K. A., Wüllner, U., & Tamgüney, G. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0254-7 · Cited by 172
Spinal cord lesions in sporadic Parkinson’s disease
Tredici, K. D., & Braak, H. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1028-y · Cited by 169
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease
Zabetian, C. P., Hutter, C. M., Factor, S. A., Nutt, J. G., Higgins, D. S., Griffith, A., Roberts, J. W., Leis, B. C., Kay, D. M., Yearout, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21157 · Cited by 165
Attentional control in Parkinson's disease is dependent on COMT val158met genotype
Williams‐Gray, C. H., Hampshire, A., Barker, R., & Owen, A. M. (2008) · Brain · doi:10.1093/brain/awm313 · Cited by 165
A systematic review of the worldwide prevalence and incidence of Parkinson's disease.
Muangpaisan, W., Mathews, A., Hori, H., & Seidel, D. (2011) · PubMed · Cited by 165
Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics
Gandhi, J., Antonelli, A. C., Afridi, A., Vatsia, S. K., Joshi, G. S., Romanov, V., Murray, I. V. J., & Khan, S. A. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0035 · Cited by 171
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study
Pogarell, O. M. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.713 · Cited by 166
Parkin Disease
Doherty, K. A., Silveira‐Moriyama, L., Parkkinen, L., Healy, D. G., Farrell, M., Mencacci, N. E., Ahmed, Z., Brett, F. M., Hardy, J., Quinn, N. P., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.172 · Cited by 164
Self-citation
Cortical motor overactivation in parkinsonian patients with L-dopa- induced peak-dose dyskinesia
Rascol, O. (1998) · Brain · doi:10.1093/brain/121.3.527 · Cited by 164
Physiotherapy versus placebo or no intervention in Parkinson's disease
Tomlinson, C. L., Patel, S., Meek, C., Clarke, C. E., Stowe, R. L., Shah, L., Sackley, C. M., Deane, K. H., Herd, C. P., Wheatley, K., et al. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002817.pub3 · Cited by 169
Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?
Derost, P. P., Ouchchane, L., Morand, D., Ulla, M., Llorca, P., Barget, M., Debilly, B., Lemaire, J., & Durif, F. (2007) · Neurology · doi:10.1212/01.wnl.0000260059.77107.c2 · Cited by 163
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease
Milber, J. M., Noorigian, J. V., Morley, J. F., Petrovitch, H., White, L., Ross, G. W., & Duda, J. E. (2012) · Neurology · doi:10.1212/wnl.0b013e318278fe32 · Cited by 163
Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease
Jenner, P. G. (1993) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb00013.x · Cited by 163
Midlife adiposity and the future risk of Parkinson’s disease
Abbott, R. D., Ross, G. W., White, L. R., Nelson, J. S., Masaki, K., Tanner, C. M., Curb, J. D., Blanchette, P. L., Popper, J. S., & Petrovitch, H. (2002) · Neurology · doi:10.1212/wnl.59.7.1051 · Cited by 163
Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review
Guedes, L. C., Ferreira, J. J., Rosa, M. M., Coelho, M. M., Bonifati, V., & Sampaio, C. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.11.004 · Cited by 162
When does Parkinson's disease begin?
Gaig, C., & TOLOSA, E. S. (2009) · Movement Disorders · doi:10.1002/mds.22672 · Cited by 162
Action and object naming in Parkinson's disease without dementia
Cotelli, M., Borroni, B., Manenti, R., Zanetti, M., Arévalo, A. L., Cappa, S. F., & Padovani, A. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01797.x · Cited by 168
Dementia is associated with Insulin Resistance in patients with Parkinson's Disease
Bosco, D., Plastino, M., Cristiano, D., Colica, C., Ermio, C., Bartolo, M. D., Mungari, P., Fonte, G., Consoli, D., Consoli, A., et al. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.12.008 · Cited by 160
Bone health in Parkinson's disease: a systematic review and meta-analysis
Torsney, K., Noyce, A. J., Doherty, K. A., Bestwick, J. P., Dobson, R., & Lees, A. J. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307307 · Cited by 161
Self-citation
M ild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy
Manenti, R., Brambilla, M., Benussi, A., Rosini, S., Cobelli, C., Ferrari, C., Petesi, M., Orizio, I., Padovani, A., Borroni, B., et al. (2016) · Movement Disorders · doi:10.1002/mds.26561 · Cited by 170
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
Palmqvist, S., Rossi, M., Hall, S., Quadalti, C., Mattsson, N., Dellavalle, S., Tideman, P., Pereira, J. B., Nilsson, M. H., Mammana, A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02450-0 · Cited by 165
Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease
Baudrexel, S., Nürnberger, L., Rüb, U., Seifried, C., Klein, J. C., Deller, T., Steinmetz, H., Deichmann, R., & Hilker, R. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.03.005 · Cited by 167
Electrophysiological evaluation of pharyngeal phase of swallowing in patients with Parkinson's disease
Erteki̇n, C., Tarlacı, S., Aydoğdu, İ., Kıylıoğlu, N., Yüceyar, N., Turman, A. B., Seçıl, Y., & Esmeli, F. (2002) · Movement Disorders · doi:10.1002/mds.10240 · Cited by 160
Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice
Ba, F., & Martin, W. R. W. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.11.007 · Cited by 160
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study
Khan, N. L. (2002) · Brain · doi:10.1093/brain/awf237 · Cited by 160
Huntington's disease – neuropathology
Vonsattel, J. P., Keller, C. E., & Cortes, E. P. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00004-5 · Cited by 164
Alpha-Synuclein Lesions in Normal Aging, Parkinson Disease, and Alzheimer Disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA)
Mikolaenko, I., Pletniková, O., Kawas, C. H., O’Brien, R., Resnick, S. M., Crain, B. J., & Troncoso, J. C. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.156 · Cited by 163
Striatal function in normal aging: Implications for Parkinson's disease
Sawle, G. V., Colebatch, J. G., Shah, A., Brooks, D. J., MARSDEN, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280611 · Cited by 159
Camptocormia in Parkinson disease: an epidemiological and clinical study
Tiple, D., Fabbrini, G., Colosimo, C., Ottaviani, D., Camerota, F., Defazio, G., & Berardelli, A. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150011 · Cited by 158
Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross‐sectional comparative study
Burn, D. J., Rowan, E. N., Minett, T., Sanders, J., Myint, P., Richardson, J., Thomas, A. J., Newby, J., Reid, J., O'Brien, J. T., et al. (2003) · Movement Disorders · doi:10.1002/mds.10455 · Cited by 160
Starnberg Trial on Epidemiology of Parkinsonism and Hypertension in the Elderly
Trenkwalder, C. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540340109020 · Cited by 158
Deficit of verb generation in nondemented patients with Parkinson's disease
Péran, P., Rascol, O., Démonet, J., Celsis, P., Nespoulous, J., Dubois, B., & Cardebat, D. (2002) · Movement Disorders · doi:10.1002/mds.10306 · Cited by 158
Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study
Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90833-8 · Cited by 156
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study
Pinter, M. M., Pogarell, O. M., & Oertel, W. H. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.4.436 · Cited by 155
Autonomic dysfunction in Parkinson's disease: A prospective cohort study
Merola, A., Romagnolo, A., Rosso, M., Suri, R., Berndt, Z., Maule, S. V., Lopiano, L., & Espay, A. J. (2017) · Movement Disorders · doi:10.1002/mds.27268 · Cited by 155
Complex networks reveal early MRI markers of Parkinson’s disease
Amoroso, N., Rocca, M. L., Monaco, A., Bellotti, R., & Tangaro, S. (2018) · Medical Image Analysis · doi:10.1016/j.media.2018.05.004 · Cited by 159
The motor phenotype of Parkinson's disease in relation to age at onset
Wickremaratchi, M. M., Knipe, D. W., Sastry, B. S. D., Morgan, E., Jones, A., Salmon, R., Weiser, R., Moran, M., Davies, D., Ebenezer, L., et al. (2011) · Movement Disorders · doi:10.1002/mds.23469 · Cited by 153
Familial parkinsonism with synuclein pathology
Krüger, R., Kuhn, W., Leenders, K. L., Sprengelmeyer, R., Müller, T., Woitalla, D., Portman, A. T., Maguire, R. P., Veenma, L., Schröder, U., et al. (2001) · Neurology · doi:10.1212/wnl.56.10.1355 · Cited by 154
Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease
Morrish, P., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.6.2097 · Cited by 153
Regional cerebral blood flow in Parkinson's disease with and without dementia
Firbank, M., Colloby, S. J., Burn, D. J., McKeith, I. G., & O'Brien, J. T. (2003) · NeuroImage · doi:10.1016/s1053-8119(03)00364-1 · Cited by 153
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease
Devos, D., Krystkowiak, P. C., Clement, F., Dujardin, K., Cottencin, O., Waucquier, N., Ajebbar, K., Thielemans, B., Kroumova, M., Duhamel, A., et al. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100016 · Cited by 153
Cytoplasmic Aggregates of Phosphorylated Extracellular Signal-Regulated Protein Kinases in Lewy Body Diseases
Zhu, J., Kulich, S. M., Oury, T. D., & Chu, C. T. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64487-2 · Cited by 153
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152
Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease
Price, S. L., Paviour, D. C., Scahill, R. I., Stevens, J., Rossor, M. N., Lees, A. J., & Fox, N. C. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.06.013 · Cited by 152
Self-citation
Olfactory Impairment Predicts Brain Atrophy in Parkinson's Disease: Figure 1.
Wattendorf, E., Welge–Lüssen, A., Fiedler, K., Bilecen, D., Wolfensberger, M., Fuhr, P., Hummel, T. R., & Westermann, B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1909-09.2009 · Cited by 152
Atypical Progressive Supranuclear Palsy With Corticospinal Tract Degeneration
Josephs, K. A., Katsuse, O., Beccano-Kelly, D. A., Lin, W.-L., Uitti, R. J., Fujino, Y., Boeve, B. F., Hutton, M. L., Baker, M., & Dickson, D. W. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000218446.38158.61 · Cited by 152
Pain sensitivity and descending inhibition of pain in Parkinson's disease
Mylius, V., Engau, I., Teepker, M., Stiasny-Kolster, K., Schepelmann, K., Oertel, W. H., Lautenbacher, S., & Möller, J. C. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.145995 · Cited by 152
Association of NO 2 and Other Air Pollution Exposures With the Risk of Parkinson Disease
Jo, S., Kim, Y., Park, K. W., Hwang, Y. S., Lee, S. H., Kim, B. J., & Chung, S. J. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1335 · Cited by 152
The differential diagnosis of Parkinson's disease
Poewe, W. H., & Wenning, G. K. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.9.s3.3.x · Cited by 152
The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism
Hedrich, K. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.16.1649 · Cited by 151
In Vivo Diagnosis of Synucleinopathies
Donadio, V. A., Wang, Z., Incensi, A., Rizzo, G., Fileccia, E., Vacchiano, V., Capellari, S., Magnani, M., Scaglione, C. L. M., Maserati, M. S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011935 · Cited by 153
Chapter 20 Neuropathological hallmarks of Alzheimer's and Parkinson's diseases
Braak, H., de Vos, R. A. I., Jansen, E. N. H., Bratzke, H., & Braak, E. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64021-2 · Cited by 150
Clinical profile of parkinsonism and Parkinson's disease in Lagos, Southwestern Nigeria
Okubadejo, N. U., Ojo, O. O., & Oshinaike, O. O. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-1 · Cited by 149
Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
Rascol, O., Arnulf, I., Paul, H. P., Brefel‐Courbon, C., Vidailhet, M., Thalamas, C., Bonnet, A. M., Descombes, S., Bejjani, B.-P. W., Fabre, N., et al. (2001) · Movement Disorders · doi:10.1002/mds.1143 · Cited by 149
Induction by Dopamine D1 Receptor Agonist ABT-431 of Dyskinesia Similar to Levodopa in Patients With Parkinson Disease
Rascol, O., Nutt, J. G., Blin, O. J., Goetz, C. G., Trugman, J. M., Soubrouillard, C., Carter, J. H., Currie, L. J., Fabre, N., Thalamas, C., et al. (2001) · Archives of Neurology · doi:10.1001/archneur.58.2.249 · Cited by 149
Course of cognitive decline in Parkinson's disease: A meta-analysis
Muslimović, D., Schmand, B. A., Speelman, J. D., & de Haan, R. J. (2007) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617707071160 · Cited by 148
Differential involvement of striato- and cerebello-thalamo-cortical pathways in tremor- and akinetic/rigid-predominant Parkinson's disease
Lewis, M. M., Du, G., Sen, S., Kawaguchi, A., Truong, Y., Lee, S., Mailman, R. B., & Huang, X. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.060 · Cited by 149
Cognitive Deficits and Psychosis in Parkinson???s Disease: A Review of Pathophysiology and Therapeutic Options
Williams-Gray, C. H., Foltynie, T., Lewis, S. J. G., & Barker, R. A. (2006) · CNS Drugs · doi:10.2165/00023210-200620060-00004 · Cited by 147
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes
Hughes, A. J., Lees, A. J., & Stern, G. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91531-e · Cited by 147
Self-citation
Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease
Kim, J., Oh, Y., Lee, K.-S., Kim, Y.-I., Yang, D., & Goldstein, D. S. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1acd · Cited by 146
Measuring mild cognitive impairment in patients with Parkinson's disease
Marras, C., Armstrong, M. J., Meaney, C. A., Fox, S. H., Rothberg, B., Reginold, W., Tang‐Wai, D. F., Gill, D., Eslinger, P. J., Zadikoff, C., et al. (2013) · Movement Disorders · doi:10.1002/mds.25426 · Cited by 146
Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease
Bouchard, T. P., Malykhin, N. V., Martin, W. R. W., Hanstock, C. C., Emery, D. J., Fisher, N., & Camicioli, R. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.002 · Cited by 152
Homozygous alpha-synuclein p.A53V in familial Parkinson's disease
Yoshino, H., Hirano, M., Stoessl, A. J., Imamichi, Y., Ikeda, A., Li, Y., Funayama, M., Yamada, I., Nakamura, Y., Sossi, V., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.022 · Cited by 139
Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology
Conn, K. J., Gao, W., McKee, A. C., Lan, M. S., Ullman, M. D., Eisenhauer, P. B., Fine, R. E., & Wells, J. M. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.026 · Cited by 144
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk
Powers, K. M., Kay, D. M., Factor, S. A., Zabetian, C. P., Higgins, D. S., Samii, A., Nutt, J. G., Griffith, A., Leis, B. C., Roberts, J. W., et al. (2007) · Movement Disorders · doi:10.1002/mds.21782 · Cited by 144
Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies
Molloy, S., Rowan, E. N., O'Brien, J. T., McKeith, I. G., Wesnes, K. A., & Burn, D. J. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.098079 · Cited by 144
Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: A case series of 115 patients
Parkin, S., Gregory, R., Scott, R., Bain, P., Silburn, P., Hall, B., Boyle, R., Joint, C., & Aziz, T. (2002) · Movement Disorders · doi:10.1002/mds.10186 · Cited by 133
Incidental Lewy body disease: Clinical comparison to a control cohort
Adler, C. H., Connor, D. J., Hentz, J. G., Sabbagh, M. N., Caviness, J. N., Shill, H. A., Noble, B., & Beach, T. G. (2010) · Movement Disorders · doi:10.1002/mds.22971 · Cited by 143
Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.
Rascol, O., Sabatini, U., Chollet, F., Fabre, N., Sénard, J., Montastruc, J., Celsis, P., Marc-Vergnes, J. P., & Rascol, A. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.5.567 · Cited by 143
Factors affecting the quality of life of patients with idiopathic Parkinson's disease-a cross-sectional study in an outpatient clinic attendees
Sławek, J. W., Derejko, M., & Lass, P. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.04.006 · Cited by 145

Authors: Gibb, W. R., & Lees, A. J.
ORCID: Gibb, W R
Lees, A J
Venue: Journal of Neurology, Neurosurgery & Psychiatry
Publisher: BMJ
Published: 1988-06-01
Volume: 51
Issue: 6
Pages: 745-752
ISSN: 0022-3050 (ISSN-L)
DOI: 10.1136/jnnp.51.6.745
PMC: PMC1033142
OpenAlex: W2132881915
Semantic Scholar: 354cd1cf28ad23a8038bb3c576ff7791b3c74543
Cited by: 3,481
References: 39
Citations by year: 2026: 78 · 2025: 130 · 2024: 152 · 2023: 143 · 2022: 131 · 2021: 158 · 2020: 164 · 2019: 152 · 2018: 138 · 2017: 156 · 2016: 163 · 2015: 115 · 2014: 149 · 2013: 123 · 2012: 138
FWCI: 3.24
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
PubMed Central (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords: Lewy bodies, Parkinson's disease, pathogenesis, neurofilaments, substantia nigra, incidental Lewy body disease, age-related prevalence, neuronal loss
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Brain, Brain Damage, Chronic, Inclusion Bodies, Child, Humans, Middle Aged, Nerve Degeneration, Parkinson Disease, Substantia Nigra

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks